Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (≥65 years of age): A phase II North Central Cancer Treatment Group study

摘要: The purpose of this study was to determine the tumor response rate and toxicity profile low-dose weekly carboplatin paclitaxel in advanced non-small-cell lung cancer (SCLC) patients 65 or more years age. Forty-nine age with non-SCLC a median 73 (range: 65-85) an Eastern Cooperative Oncology Group performance status 0, 1, 2 31%, 47%, 22% patients, respectively, were treated evaluated. Patients received (AUC = 2) 50 mg/m2 on days 8, 15 4-week cycle. overall confirmed 14% (95% CI: 4.7%, 32.5%) no complete responses. 1-year survival 31% 20%, 48%). There one treatment-related death, there two grade IV allergic reactions chemotherapy. No other V toxicities observed. only three episodes III myelosuppression. Low-dose paclitaxel, as prescribed trial, provides modest activity treatment However, relatively mild observed trial suggests that regimen might remain option for at increased risk myelosuppression poor status.